Loading
Loading
Research Overview
Endogenous neuropeptide that activates GPR54/Kiss1R receptors on GnRH neurons in the hypothalamus, stimulating LH/FSH pulse amplitude and frequency; proposed as a safer alternative to hCG for triggering final oocyte maturation in IVF protocols.
Kisspeptin neurons in the hypothalamic arcuate nucleus and anteroventral periventricular nucleus integrate metabolic, hormonal, and environmental signals to regulate the pulsatile release of GnRH from hypothalamic neurons, which in turn drives FSH and LH release from the pituitary. Preclinical research has used kisspeptin, its receptor agonists, and transgenic animal models to dissect the neural circuits through which the HPG axis is regulated, establishing kisspeptin signalling as an essential node in reproductive neuroendocrinology.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, kisspeptin (kiss1) peptide has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Kisspeptin (KISS1) Peptide research is most relevant to protocols examining:
GPR54/Kiss1R receptor biology and GnRH neuron research
IVF oocyte maturation trigger studies
lower OHSS risk than hCG
HPG axis pulse regulation investigations
Researchers studying upstream hypothalamic fertility signalling
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Primary outcomes are typically strongest in this window. Human trial literature provides benchmarks for comparison.
Washout & review
Allow full washout (~5× half-life: ~Hours). Review data, confirm baseline recovery before any repeat protocol.
Endogenous neuropeptide that activates GPR54/Kiss1R receptors on GnRH neurons in the hypothalamus, stimulating LH/FSH pulse amplitude and frequency; proposed as a safer alternative to hCG for triggering final oocyte maturation in IVF protocols.
| Parameter | Value |
|---|---|
| Dose range | Under investigation (nmol/kg IV in trials) |
| Schedule | Protocol-dependent |
| Route | Subcutaneous, Intravenous |
| Half-life | ~Hours |
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.